Understanding differences in HIV/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico

Harm Reduction Journal

Volumn 13, Issue 1, 2016, Pages

  Abadie, Roberto ^a   Welch Lazoritz, Melissa ^a   Gelpi Acosta, Camila ^b   Reyes, Juan Carlos ^c   Dombrowski, Kirk ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b University of New York   (United States)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

HIV HCV risk factors; Injection equipment; PWID; Rural Puerto Rico; Sharing

Indexed keywords

WATER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; COOKER; COTTON; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FEMALE; HEALTH EDUCATION; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL DEVICE; MISCELLANEOUS NAMED GROUPS; MIXED INFECTION; PEOPLE WHO INJECT DRUG; PREVALENCE; PUERTO RICO; RISK FACTOR; RURAL AREA; SEXUAL BEHAVIOR; ADOLESCENT; COMPLICATION; DRUG USE; HIV INFECTIONS; MIDDLE AGED; NEEDLE SHARING; PSYCHOLOGY; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DRUG USERS; FEMALE; HEALTH EDUCATION; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEEDLE SHARING; PREVALENCE; PUERTO RICO; RISK FACTORS; RISK-TAKING; RURAL POPULATION; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84960120861     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-016-0099-9     Document Type: Article

References (52)

1. Diaz T, Buehler J, Castro K, Ward J. AIDS trends among Hispanics in the United States. Am J Pub Health. 1993;83:504-9.
2. Robles RR, Colón HM, Sahai H, Matos TD, Marrero CA, Reyes JC. Behavioral risk factors and human immunodeficiency virus (HIV) prevalence among intravenous drug users in Puerto Rico. Am J Epidemiol. 1992;135:531-40.
3. Selik R, Castro K, Pappaioanou M. Racial/ethnic differences in the risk of AIDS in the United States. Am J Pub Health. 1988;78:1539-45.
4. Deren S, Robles R, Andia J, Colon H, Kang S, Perlis T. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York. J Acquir Immune Defic Syndr. 2001;26:164-9.
5. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011, vol. 23. 2013.
6. Department of Health of Puerto Rico. Perfil Epidemiológico Integrado para la Prevención del VIH en Puerto Rico, 2005-2011. San Juan, Puerto Rico: Department of Health of Puerto Rico; 2012.
7. Reyes JC, Colon H, Robles RR, et al. Prevalence and correlates of hepatitis c virus infection among street-recruited injection drug users in San Juan, Puerto Rico. J Urban Health. 2006;83(6):1105-13.
8. Bao YP, Li ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS. 2009;20:399-405.
9. Rahimi-Movaghar A, Razaghi EM, Sahim-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14:28-33.
10. Hahn A, Page-Schafer K, Lum PJ, et al. Hepatitis c virus seroconversion among young injection drug users: relationships and risk. J Infect Dis. 2002;186:1558-64.
11. Doerrbecker J, Behrendt P, Matheu-Gelabert P, et al. Transmission of Hepatitis C Among People Who Inject Drugs: Viral Stability And Association with Drug Preparation Equipment. J Infect Dis. 2013; 207(2):281-7.
12. Pouget E, Hagan H, Des Jarlais D. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2012;107:1057-65.
13. Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risk transmission. J Infect Dis. 2014;209:1205-11.
14. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202:984-90.
15. Miller CL, Johnston C, Spittal RM, Liu K, Laliberte N, Montaner JS, et al. Opportunities for prevention: hepatitis C prevalence in a cohort of young injection drug users. Hepatol. 2002;36:733-42.
16. Dolan K, Teutsch S, Schever N, Levy M, Rawlinson W, Lloyd A, et al. Incidence and risk for acute hepatitis c infection during imprisonment in Australia. Eur J Epidemiol. 2010;25:143-8.
17. Rolls D, Sacks-Davis R, Jenkinson R, et al. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLOS One. 2013;8:e78286.
18. Pérez CM, Albizu-García CE, Torres EA. Tackling the health challenge posed by hepatitis C in Puerto Rico: a call for immediate public health actions. P R Health Sci J. 2015;34:53-9.
19. Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104:2226-32.
20. Hagan H, Thiede H, Noel S, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-6.
21. Hagan H, Des Jarlais D, Friedman S, Purchase D, Alter MJ. Reduced risk of hepattis B and hepatitis C among injection drug users in the Tacoma Syringe Exchange Program. Am J Public Health. 1995;85:1531-7.
22. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27-39.
23. López LM, de Saxe Zerden L, Bourgois P, et al. HIV/AIDS in Puerto Rican people who inject drugs: policy considerations. Am J Public Health. 2015;105(1):e3.
24. Abdul-Quander AS, Heckathorn DD, McKnight C, Bramson H, Nemeth C, Sabin K, et al. Effectiveness of respondent driven sampling for recruiting drug users in New York City: findings from a pilot study. J Urban Health. 2006;83:459-76.
25. Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Social Problems. 2002;49:11-34.
26. Heckathorn DD. Extensions of respondent-driven sampling: analyzing continuous variables and controlling for differential recruitment. Sociol Methodol. 2007;37:151-207.
27. Johnston LG, Chen YH, Silva-Santisteban A, Raymond HF. An empirical examination of respondent driven sampling design effects among HIV risk groups from studies conducted around the world. AIDS Behav. 2013;17:2202-10.
28. Cagle H, Fisher D, Senter T, Thurmond R. Classifying skin lesions of injection drug users: a method for corroborating disease risk. DHHS Pub. No. (SMA) 03-3771. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2002.
29. Fisher D, Needle R, Weatherby N, Brown B, Booth R, Williams M. Reliability of drug user self report. In: Abstract Book, IX International Conference on AIDS, June 6-11, 1993; Berlin, Germany, Abstract no. PO-C35-3355.
30. Volz E, Wejnert C, Cameron C, et al. Respondent-driven sampling analysis tool (RDSAT) Version 7.1. Ithaca, NY: Cornell University; 2012.
31. Handcock MS, Gile KJ, Fellows IE, et at. Package "RDS." 2015 [cited 2015 Nov 29]; Available from: ftp://204.45.81.82/cran/web/packages/RDS/RDS.pdf.
32. Garten R, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33:182-8.
33. Abdala N, Carney J, Durante A, et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int J STD AIDS. 2003;14:697-703.
34. Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, Mezzelani P, et al. Hepatitis C virus infection prevalence, predictor variables and prevention opportunities among drug users in Italy. J Viral Hepat. 2003;10:394-400.
35. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;8:52-358.
36. Nelson P, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2001;378:571-83.
37. Kapaolia F, Vlahov D, Des Jarlais D, et al. Does bleach disinfection of syringes protect against hepatitis infection among young adult injection drug users? Epidemiology. 2002;13:738-41.
38. Binka N, Paintsill E, Patel A, Lindenbach B, Heimer R. Disinfection of syringes contaminated with hepatitis C virus by rinsing with household products. Open Forum of Infect Dis. 2015;2(1). doi: 10.1093/ofid/ofv017.
39. Thorpe N, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645-53.
40. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62.
41. Hagan H, Thiede H, Weiss NS, et al. Sharing drug preparation equipment as a risk factor for hepatitis C. Am J Publ Health. 2001;91(1):42-6.
42. Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injection paraphernalia. J Viral Hepat. 2014;21(1):25-32.
43. Colon HM, Robles RR, Deren S, et al. Between-city variation in frequency of injection among Puerto Rican injection drug users: East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr. 2001;27:405-13.
44. Perez CM, Suarez E, Torres E. Epidemiology of hepatitis C infection and its public health implications in Puerto Rico. PR Health Sci J. 2004;23(2):11-28.
45. Perez C, Marrero E, Melendez M, et al. Seroepidemiology of viral hepatitis, HIV and herpex simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis. 2010;10:76.
46. Strathdee S, Stockman JK. Epidemiology of HIV among injection and non-injection drug users: current trends and implications for interventions. Cur HIV/AIDS Rep. 2010;7:99-106.
47. Grebely J, Mattews GV, Lloyd AR, et al. Elimination of hepatitis C virus infection among people who inject drugs throw treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013;57(1):1014-20.
48. Woods E, Kerr T, Motaner J, et al. Rationale for evaluating North America first medically supervised safer-injection facility. The Lancet. 2004;4(5):301-6.
49. Dutta A, Wirtz A, Baral S, et al. Key harm reduction interventions and their impact on the reduction of risk behavior and HIV Incidence among people who inject drugs in low income and middle income countries. Curr Opin HIV AIDS. 2012;7(4):362-8.
50. Page K, Morris MD, Hahn J, et al. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(2):32-8.
51. Deren S, Gelpí-Acosta C, Albizu-García CE, et al. Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach. Am J Public Health. 2014;104(11):2030-6.
52. Robertson A, Garfein RS, Wagner KD, et al. Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA., United States: a binational mixed methods research agenda. Harm Reduct J. 2014. doi: 10.1186/1477-7517-11-4.